AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

16.340

+0.6704.28%

Volume:4.72M

Turnover:77.75M

Market Cap:5.53B

PE:122.09

High:17.650

Open:17.500

Low:15.850

Close:15.670

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:3.26

T/O Rate:1.72%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.134

EPS(LYR):-0.030

ROE:7.36%

ROA:2.71%

PB:8.09

PE(LYR):-551.93

Loading ...

Overview Company News Filings

Telix completes enrolment in IPAX-2 Phase 1 glioblastoma trial of TLX101-Tx

Ipax-2 Study of Tlx101-Tx in First-Line Glioblastoma Completes Enrolment and Confirms Dosing

THOMSON REUTERS

Telix Pharmaceuticals Shares Fall 3% After Entering Collaboration to Explore Prostate Cancer Imaging in New Treatment Approaches

MT Newswires Live

Telix Announces Collaborations to Explore Psma-Pet Imaging in Emerging Prostate Cancer Treatment Approaches

THOMSON REUTERS

New Kidney and Brain Imaging Data Might Change The Case For Investing In Telix (ASX:TLX)

Simply Wall St.

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones

Simply Wall St.

Lotus Resources Most Shorted Stock on Australian Bourse, ASIC Data Shows

MT Newswires Live

ASX Biggest Losers

MT Newswires Live

Telix CEO Christian Behrenbruch acquires ordinary shares worth AUD 1.01 million

Telix study shows Zircaix PET/CT predicts kidney cancer beyond clear-cell RCC

Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares

Simply Wall St.

Does New TLX597-Tx Data And Pipeline Progression Change The Bull Case For Telix (ASX:TLX)?

Simply Wall St.

BUZZ-Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application

BRIEF-Telix Pharmaceuticals Says TLX101-PX (PIXLUMI®) MAA Accepted In Europe

Telix TLX101-Px glioma imaging MAA accepted for EU review

Telix Pharmaceuticals Ltd - Tlx101-Px (Pixlumi®) Maa Accepted in Europe

THOMSON REUTERS

Telix Phase 2 OPTIMAL-PSMA trial shows favorable dosimetry for TLX597-Tx radioligand therapy

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration

Simply Wall St.

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

Telix to host webinar on next-generation PSMA-targeted prostate cancer therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/TLX.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":16.34,"timestamp":1789366320000,"preClose":15.67,"halted":0,"volume":4723800,"delay":0,"changeRate":0.04275686024250159,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13383263694603537,"marketStatus":"Closed","change":0.67,"latestTime":"09-14 16:12:00 AEST","open":17.5,"high":17.65,"low":15.85,"amount":77751632,"amplitude":0.114869,"askPrice":16.4,"askSize":650,"bidPrice":16.2,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.13383263694603537,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":15.67,"openAndCloseTimeList":[[1789344000000,1789365600000]],"volumeRatio":3.261644,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.67,"auctionPrice":16.34,"auctionVolume":402421,"auctionTime":1789366211720,"referencePrice":16.34,"referenceTime":1789376403764,"auction":3,"marketStatus":"盘后竞价","timestamp":1789366211720}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029605,"volumeRatio":3.261644,"shares":338721355,"dividePrice":0,"high":17.65,"amplitude":0.114869,"preClose":15.67,"low":15.85,"week52Low":8.26,"pbRate":"8.09","psRate":"4.43","week52High":18.32,"institutionHeld":0,"latestPrice":16.34,"committee":0.212121,"eps":0.13383263694603537,"divideRate":0,"volume":4723800,"delay":0,"ttmEps":0.13383263694603537,"open":17.5,"prevYearClose":11.2,"prevWeekClose":15.67,"prevMonthClose":15.36,"prevQuarterClose":16.58,"fiveDayClose":16.25,"twentyDayClose":16.45,"sixtyDayClose":14.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636521001","title":"Telix completes enrolment in IPAX-2 Phase 1 glioblastoma trial of TLX101-Tx","url":"https://stock-news.laohu8.com/highlight/detail?id=2636521001","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636521001?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:01","pubTimestamp":1779138079,"startTime":"0","endTime":"0","summary":"Telix completed enrolment in its Phase 1 IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma.Interim safety observations have been positive, with dosing reaching the study maximum without dose-limiting toxicities; final confirmation of the maximum tolerated dose will come later when the trial completes, so results have not yet been formally presented.The update supports continued development of TLX101-Tx for first-line glioblastoma, a potential expansion beyond its ongoing Phase 3 IPAX BrIGHT program in recurrent disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL4BCY9y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014005.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4112","SG9999014039.USD","BK4588","TLX.AU","BK7067","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636015570","title":"Ipax-2 Study of Tlx101-Tx in First-Line Glioblastoma Completes Enrolment and Confirms Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636015570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636015570?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:00","pubTimestamp":1779138000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA2ZMN1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046412","title":"Telix Pharmaceuticals Shares Fall 3% After Entering Collaboration to Explore Prostate Cancer Imaging in New Treatment Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046412","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636046412?lang=en_us&edition=fundamental","pubTime":"2026-05-18 11:57","pubTimestamp":1779076630,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  shares fell 3% in recent Monday trade after the company said late Friday it has entered into letters of intent to pursue collaborations with EDAP TMS and Profound Medical, developers of minimally invasive and image-guided ablative treatment technologies for prostate cancer.The company said in a statement that the collaborations will explore the investigational use of its prostate-specific membrane antigen positron emission tomography imaging agents Gozellix and Illuccix with robotic high-intensity focused ultrasound and other image-guided therapies designed to treat localized prostate cancer, including transurethral ultrasound ablation.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","BK4139","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635831780","title":"Telix Announces Collaborations to Explore Psma-Pet Imaging in Emerging Prostate Cancer Treatment Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2635831780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635831780?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:30","pubTimestamp":1778841000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA98SRNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDAP","BK7067","BK4082","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635774067","title":"New Kidney and Brain Imaging Data Might Change The Case For Investing In Telix (ASX:TLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635774067","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635774067?lang=en_us&edition=fundamental","pubTime":"2026-05-15 11:38","pubTimestamp":1778816299,"startTime":"0","endTime":"0","summary":"In early May 2026, Telix Pharmaceuticals reported new independent Phase 3 ZIRCON analyses in European Urology showing TLX250-Px PET/CT may predict malignancy across a broad range of renal cancer subtypes, alongside progress of its glioma imaging candidate TLX101-Px with a validated European marketing authorization application now under active review.\nThese updates highlight how Telix’s radiopharmaceutical imaging portfolio could extend beyond clear cell kidney cancer into non-clear cell...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/new-kidney-and-brain-imaging-data-might-change-the-case-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/new-kidney-and-brain-imaging-data-might-change-the-case-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635076495","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076495","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635076495?lang=en_us&edition=fundamental","pubTime":"2026-05-14 09:45","pubTimestamp":1778723107,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after the FDA accepted its resubmitted New Drug Application for brain imaging agent Pixclara and the company reaffirmed its FY2026 revenue guidance alongside several late stage pipeline updates.\nSee our latest analysis for Telix Pharmaceuticals.\nAt A$14.52, Telix’s stock has given investors a 59.91% 90 day share price return and a 27.82% year to date share price return, yet the 1 year total shareholder return is down 43.19%, so near term...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","TLX.AU","TLX","BK4588","BK7067","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750093","title":"Lotus Resources Most Shorted Stock on Australian Bourse, ASIC Data Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750093","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635750093?lang=en_us&edition=fundamental","pubTime":"2026-05-14 09:05","pubTimestamp":1778720718,"startTime":"0","endTime":"0","summary":"Lotus Resources  was the most shorted stock on the Australian bourse as of May 7, with 16.02% of its total share registry reported as short positions, according to data from the Australian Securities and Investments Commission .Domino's Pizza Enterprises  was the second most shorted stock, with 15.59% of its share registry reported as short positions. Telix Pharmaceuticals  was at the third top spot, with 15.31% of its share registry reported as short positions.The regulator cautioned that its aggregated short position reports are reliant on the accuracy of reports received from individual short sellers.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU2360107325.USD","ON","BK4512","LU2357305700.SGD","LU1978683503.SGD","BK7067","BK4585","IE00BD6J9T35.USD","LU1861214812.USD","BK7083","BK4107","BK4605","LU1861215975.USD","LU1861220033.SGD","XJO.AU","LOT.AU","XAO.AU","TLX.AU","ASIC","LU2298322129.HKD","LU1720051017.SGD","LU1720051108.HKD","IE00BFMHRM44.USD","BK7095","LU1548497426.USD","BK7137","LU1854103824.USD","LU1861219969.SGD","DMP.AU","XKO.AU","LU0348723411.USD","IE00BZ199S13.USD","LU0724618433.USD","LU0124384867.USD","BK4141","LU1854104046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634735484","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2634735484","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634735484?lang=en_us&edition=fundamental","pubTime":"2026-05-11 10:11","pubTimestamp":1778465495,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Monday.CSL : -18%, AU$97.86Emerald Resources : -4%, AU$5.80Codan : -3%, AU$38.87Super Retail Group : -2%, AU$11.33Westpac Banking : -2%, AU$36.56Regis Resources : -2%, AU$6.68NexGen : -2%, AU$16.67National Australia Bank : -2%, AU$37.52Telix Pharmaceuticals : -1%, AU$14.48Paladin Energy : -2%, AU$12.22","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7083","NXG.AU","BK7511","BK7135","BK7084","BK7067","BK7509","TLX.AU","BK7104","NAB.AU","SUL.AU","EMR.AU","RRL.AU","WBC.AU","CDA.AU","CSL.AU","PDN.AU","BK7501","BK7128"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633621641","title":"Telix CEO Christian Behrenbruch acquires ordinary shares worth AUD 1.01 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633621641","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633621641?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:32","pubTimestamp":1778117578,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals: MD and Group CEO Christian Behrenbruch reported purchases of 67,935 ordinary shares through Elk River Holdings Pty Ltd.Indirect beneficial ownership rose to 20,742,935 ordinary shares.Shares were bought at average prices of AUD 14.48 and AUD 14.87.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL2NTBh6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Telix CEO Christian Behrenbruch acquires ordinary shares worth AUD 1.01 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633838961","title":"Telix study shows Zircaix PET/CT predicts kidney cancer beyond clear-cell RCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2633838961","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633838961?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:00","pubTimestamp":1777928422,"startTime":"0","endTime":"0","summary":"Telix published an independent analysis of Phase 3 ZIRCON trial data in European Urology, with results already presented as a new journal publication.Study found TLX250-Px  PET/CT imaging could help identify kidney cancer across multiple renal tumor subtypes, extending potential use beyond clear cell renal cell carcinoma.Findings suggest a positive scan may support clinical decision-making by distinguishing malignant disease from less aggressive tumors, with implications for managing non-clear cell renal cell carcinoma.Telix noted these exploratory results were not part of its Biologics License Application submission, which remains focused on detecting clear cell renal cell carcinoma in primary renal masses.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL4tFmsc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4588","BK7067","LU2210149790.SGD","NDAQ","SG9999014039.USD","LU0314104364.USD","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4112","SG9999014021.USD","TLX.AU","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632705906","title":"Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2632705906","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632705906?lang=en_us&edition=fundamental","pubTime":"2026-05-03 06:02","pubTimestamp":1777759366,"startTime":"0","endTime":"0","summary":"Those following along with Telix Pharmaceuticals Limited ( ASX:TLX ) will no doubt be intrigued by the recent purchase...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/insider-buying-telix-pharmaceuticals-co-founder-bought-us997","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/insider-buying-telix-pharmaceuticals-co-founder-bought-us997","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623733","title":"Does New TLX597-Tx Data And Pipeline Progression Change The Bull Case For Telix (ASX:TLX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623733","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623733?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:45","pubTimestamp":1777668303,"startTime":"0","endTime":"0","summary":"In late April 2026, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA dosimetry data for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in non-target organs and supporting further evaluation in earlier-stage disease, while also progressing a Regeneron collaboration and a European review of its glioma imaging agent TLX101-Px.\nThese developments highlight how Telix is trying to build an integrated radiopharmaceutical platform, pairing next-generation...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-new-tlx597-tx-data-and-pipeline-progression-change-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-new-tlx597-tx-data-and-pipeline-progression-change-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632968716","title":"BUZZ-Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application","url":"https://stock-news.laohu8.com/highlight/detail?id=2632968716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632968716?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:28","pubTimestamp":1777598939,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application** Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.7% to A$15.55 in early trade, their highest level since April 14** Biopharma major says marketing authorisation application for its TLX101-Px therapy has been validated and accepted for review in Europe** TLX101-Px is an imaging candidate for characterisation of glioma, a form of brain cancer** Says application, which covers commercially significant European markets, has now moved into a 210-day active assessment phase** Stock up 37.4% YTD, including the day's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL4N41E018:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632957126","title":"BRIEF-Telix Pharmaceuticals Says TLX101-PX (PIXLUMI®) MAA Accepted In Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2632957126","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632957126?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:15","pubTimestamp":1777598129,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Says TLX101-PX  MAA Accepted In EuropeMay 1  - Telix Pharmaceuticals Ltd TLX.AX:TLX101-PX  MAA ACCEPTED IN EUROPETLX101-TX GRANTED ORPHAN DRUG DESIGNATION IN EUROPE AND U.S.Further company coverage: TLX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41D1O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632676886","title":"Telix TLX101-Px glioma imaging MAA accepted for EU review","url":"https://stock-news.laohu8.com/highlight/detail?id=2632676886","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632676886?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:15","pubTimestamp":1777587355,"startTime":"0","endTime":"0","summary":"Telix European marketing authorization application for TLX101-Px  validated, accepted for review.Review enters 210-day active assessment phase under European regulator process.Positive Day 210 outcome would clear path for national marketing authorizations shortly after.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL24tFDx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4588","SG9999014013.SGD","BK4585","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014005.SGD","LU2210150020.SGD","TLX.AU","IE00BKPKM429.USD","LU0314104364.USD","SG9999014039.USD","BK7067","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662674","title":"Telix Pharmaceuticals Ltd - Tlx101-Px (Pixlumi®) Maa Accepted in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662674?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:43","pubTimestamp":1777585438,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D1O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631280524","title":"Telix Phase 2 OPTIMAL-PSMA trial shows favorable dosimetry for TLX597-Tx radioligand therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2631280524","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631280524?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:17","pubTimestamp":1777497427,"startTime":"0","endTime":"0","summary":"Telix presented initial dosimetry results from randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx at IPCS 2026, outlining a safety profile that could support more intensive dosing.Data indicated reduced radiation exposure to salivary glands and kidneys, a finding that could lower treatment-limiting side effects and improve tolerability.Telix framed results as supportive of moving TLX597-Tx into earlier-stage metastatic hormone-sensitive prostate cancer, where quality-of-life constraints can limit use of existing radioligand therapies.Company plans to initiate OPTIMAL-E, a Phase 2 study in androgen pathway-sensitive metastatic prostate cancer, to extend evaluation beyond advanced disease.Program sits alongside TLX591-Tx, Telix’s Phase 3 ProstACT Global candidate in mCRPC, positioning portfolio for stage-specific prostate cancer treatment strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6t2JZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631527403","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2631527403","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631527403?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:09","pubTimestamp":1777496942,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has drawn fresh attention after announcing plans to showcase OPTIMAL-PSMA 2 data on its TLX597-Tx candidate, alongside upcoming TLX591-Tx trial results and a new collaboration with Regeneron Pharmaceuticals.\nSee our latest analysis for Telix Pharmaceuticals.\nThese clinical updates and the Regeneron partnership arrive during a period of strong share price momentum, with Telix recording a 15.03% 1 month share price return and a 35.38% 3 month share price return,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX.AU","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516078","title":"Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516078?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:01","pubTimestamp":1777464060,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals got a quiet reception from Wall Street on Wednesday despite a first-quarter earnings beat, as investors remain fixated on the release of key data later this year.The Tarrytown, N.Y.-based drugmaker posted adjusted earnings of $9.47 a share, handily beating the $8.89 Wall Street had anticipated. Revenue ticked higher to $3.61 billion from $3.03 billion last year, surpassing analysts' calls for $3.48 billion.Sales of Dupixent, the blockbuster anti-inflammatory drug co-developed with Sanofi, rose 33% to $4.9 billion in the first quarter. Dupixent recently was approved by both U.S. and European regulators for young children with chronic spontaneous urticaria, and was separately approved by the Food and Drug Administration to treat allergic fungal rhinosinusitis.Other products didn't fare as well. Sales of the standard formulation of Eylea, a prescription ophthalmologic medicine, fell 10% to $941 million. However, sales of higher-dose Eylea HD surged 52% to $468 mi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0053666078.USD","LU2089984988.USD","LU2106854487.HKD","BK4588","LU0889565916.HKD","LU2023250504.SGD","LU0320765992.SGD","LU1974910355.USD","BK7067","BK4585","LU0114720955.EUR","BK4139","LU2237438978.USD","LU0289739699.SGD","REGN","BK4007","LU0882574055.USD","LU0823434583.USD","IE00BFXG1179.USD","LU2362541273.HKD","LU1917777945.USD","LU0823434740.USD","SNY","LU2468319806.SGD","LU0823416689.USD","LU0058720904.USD","TLX.AU","LU2362541513.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630469683","title":"Telix to host webinar on next-generation PSMA-targeted prostate cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2630469683","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630469683?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:07","pubTimestamp":1777331262,"startTime":"0","endTime":"0","summary":"Telix will host an educational webinar on PSMA-targeted radionuclide therapy on April 30, 2026 at 9:30 a.m. AEST.Session will also run on April 29, 2026 at 7:30 p.m. EDT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL8LZqpR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":198,"code":"91000000","status":"200"}]}}